← Leaderboards
Don J Diamond
University Of Southern California
$24,317,616
Attributed
$38,283,228
Total exposure
29
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,283,228 · 29
By mechanism
R01$17,655,523 · 6
U01$15,523,610 · 1
P01$2,951,090 · 1
M01$1,217,119 · 17
R21$862,300 · 2
P51$73,586 · 2
Top collaborators
- Peter A Barry9 shared
- Cynthia E Fisher6 shared
- Abhijit Prakash Limaye6 shared
- Sayan Dasgupta3 shared
- Ying Qing Chen1 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Lon S Schneider$40,841,066
- Alan S. Wayne$836,852
Others in their field
Top investigators on “Cytomegalovirus”
- Constance Ann Benson · University Of California, San Diego$154,530,762
- Curtis L Meinert · Johns Hopkins University$72,267,482
- Louis J. Picker · Oregon Health And Science University$67,787,971
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Dan H. Barouch · Fred Hutchinson Cancer Center$34,316,808
- Jay A Nelson · Oregon Health & Science University$28,085,685
Research focus
CytomegalovirusVaccinesImmune ResponseVaccinationEvaluationImmunityPreventClinical ResearchDoseClinical TrialsTransplant RecipientsT-LymphocyteImmunogenicityViralResponseSafetyViremiaImmuneBaseCytomegalovirus InfectionsModified Vaccinia Virus AnkaraAntigensHealthy VolunteerToxic Effect
Grant awards (82)
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$3,209,830
U01 · FY2025 · AI
Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation$648,910
R01 · FY2025 · CA · contact PI
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$2,672,910
U01 · FY2024 · AI
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$658,822
U01 · FY2024 · AI
Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation$616,432
R01 · FY2024 · CA · contact PI
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$3,331,802
U01 · FY2023 · AI
Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation$688,080
R01 · FY2023 · CA · contact PI
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$3,354,504
U01 · FY2022 · AI
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$2,295,742
U01 · FY2021 · AI
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection$721,537
R01 · FY2018 · CA · contact PI
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection$710,976
R01 · FY2017 · CA · contact PI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine$539,228
R01 · FY2017 · CA · contact PI
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry$724,200
R01 · FY2016 · AI · contact PI
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection$710,976
R01 · FY2016 · CA · contact PI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine$539,228
R01 · FY2016 · CA · contact PI
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry$737,660
R01 · FY2015 · AI · contact PI
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection$710,976
R01 · FY2015 · CA · contact PI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine$533,838
R01 · FY2015 · CA · contact PI
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry$750,339
R01 · FY2014 · AI · contact PI
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection$739,531
R01 · FY2014 · CA · contact PI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine$663,711
R01 · FY2014 · CA · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$565,290
R01 · FY2014 · AI
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC$212,663
R21 · FY2014 · CA · contact PI
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry$614,609
R01 · FY2013 · AI · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$528,777
R01 · FY2013 · AI
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC$182,700
R21 · FY2013 · CA · contact PI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine$84,049
R01 · FY2013 · CA · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$504,976
R01 · FY2012 · AI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine$29,183
R01 · FY2012 · CA · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$615,364
R01 · FY2011 · AI
Vaccine-Induced Immunity to CMV$706,056
P01 · FY2010 · CA · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$585,050
R01 · FY2010 · AI
RHESUS CMV INFECTION OF IMMUNOSUPPRESSED CMV NATIVE RHESUS MONKEYS$37,989
P51 · FY2010 · RR · contact PI
Vaccine-Induced Immunity to CMV$659,845
P01 · FY2009 · CA · contact PI
CLINICAL TRIAL: LIPOPEPTIDE VACCINE WITH ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS$370,659
M01 · FY2009 · RR · contact PI
INFLUENZA-SPECIFIC HUMORAL AND CELLULAR IMMUNITY AFTER VACCINATION IN RECIPIENTS$177,401
M01 · FY2009 · RR · contact PI
RHESUS CMV INFECTION OF IMMUNOSUPPRESSED CMV NATIVE RHESUS MONKEYS$35,597
P51 · FY2009 · RR · contact PI
DETECTION OF CELLULAR/IMMUNE RESPONSES TO MITF IN NORMAL SUBJECTS AND$33,626
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: IMMUNOLOGIC STUDIES FROM BONE MARROW DONORS AND VOLUNTEERS FOR T$4,637
M01 · FY2009 · RR · contact PI
Vaccine-Induced Immunity to CMV$633,228
P01 · FY2008 · CA · contact PI
Peptide Vaccine To Prevent CMV Disease After HSCT$468,767
R01 · FY2008 · CA · contact PI
Peptide Vaccine To Prevent CMV Disease After HSCT$110,460
R01 · FY2008 · CA · contact PI
INFLUENZA-SPECIFIC HUMORAL AND CELLULAR IMMUNITY AFTER VACCINATION IN RECIPIENTS$85,325
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: LIPOPEPTIDE VACCINE WITH ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS$57,683
M01 · FY2008 · RR · contact PI
DETECTION OF CELLULAR/IMMUNE RESPONSES TO MITF IN NORMAL SUBJECTS AND$10,816
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: IMMUNOLOGIC STUDIES FROM BONE MARROW DONORS AND VOLUNTEERS FOR T$2,405
M01 · FY2008 · RR · contact PI
Vaccine-Induced Immunity to CMV$580,867
P01 · FY2007 · CA · contact PI
Peptide Vaccine To Prevent CMV Disease After HSCT$466,660
R01 · FY2007 · CA · contact PI
Peptide Vaccine To Prevent CMV Disease After HSCT$107,242
R01 · FY2007 · CA · contact PI
LIPOPEPTIDE VACCINE WITH ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS$2,907
M01 · FY2007 · RR · contact PI
IMMUNOLOGIC STUDIES FROM BONE MARROW DONORS AND VOLUNTEERS FOR THE STUDY OF CMV$1,939
M01 · FY2007 · RR · contact PI
Peptide Vaccine To Prevent CMV Disease After HSCT$469,211
R01 · FY2006 · CA · contact PI
Vaccine-Induced Immunity to CMV$371,094
P01 · FY2006 · CA · contact PI
CpG DNA:Epitope Fusion Peptide Conjugates as HIV Vaccine$251,937
R21 · FY2006 · AI · contact PI
Peptide Vaccine To Prevent CMV Disease After HSCT$107,229
R01 · FY2006 · CA · contact PI
IMMUNOLOGIC STUDIES FROM BONE MARROW DONORS AND VOLUNTEERS FOR THE STUDY OF CMV$5,445
M01 · FY2006 · RR · contact PI
LIPOPEPTIDE VACCINE WITH ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS$2,178
M01 · FY2006 · RR · contact PI
Peptide Vaccine To Prevent CMV Disease After HSCT$469,182
R01 · FY2005 · CA
CpG DNA:Epitope Fusion Peptide Conjugates as HIV Vaccine$215,000
R21 · FY2005 · AI
Peptide Vaccine To Prevent CMV Disease After HSCT$104,106
R01 · FY2005 · CA
IMMUNOLOGIC STUDIES FROM BONE MARROW DONORS AND VOLUNTEERS FOR THE STUDY OF CMV$34,088
M01 · FY2005 · RR
LIPOPEPTIDE VACCINE WITH ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS$17,561
M01 · FY2005 · RR
Immunologic Studies from Bone Marrow Donors and Volunteers for the Study of CMV.$27,815
M01 · FY2004 · RR
LIPOPEPTIDE VACCINE TO PREVENT HCMV INFECTION AFTER BMT$279,778
R01 · FY2002 · CA
BONE MARROW DONORS &VOLUNTEERS FOR STUDY OF CMV$0
M01 · FY2002 · RR
ACQUISITION OF IMMUNITY TO CYTOMEGALOVIRUS$0
P01 · FY2002 · CA
LIPOPEPTIDE VACCINE W/ ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS$0
M01 · FY2002 · RR
VACCINATION FOR CMV IN AIDS PATIENTS UNDERGOING HAART$413,657
R01 · FY2001 · AI
LIPOPEPTIDE VACCINE TO PREVENT HCMV INFECTION AFTER BMT$276,381
R01 · FY2001 · CA
LIPOPEPTIDE VACCINE W/ ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS$155,764
M01 · FY2001 · RR
BONE MARROW DONORS &VOLUNTEERS FOR STUDY OF CMV$155,764
M01 · FY2001 · RR
VACCINATION FOR CMV IN AIDS PATIENTS UNDERGOING HAART$58,173
R01 · FY2001 · AI
ACQUISITION OF IMMUNITY TO CYTOMEGALOVIRUS$0
P01 · FY2001 · CA
LIPOPEPTIDE VACCINE W/ ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS$0
M01 · FY2001 · RR
BONE MARROW DONORS &VOLUNTEERS FOR STUDY OF CMV$0
M01 · FY2001 · RR
VACCINATION FOR CMV IN AIDS PATIENTS UNDERGOING HAART$441,786
R01 · FY2000 · AI
LIPOPEPTIDE VACCINE TO PREVENT HCMV INFECTION AFTER BMT$319,971
R01 · FY2000 · CA
LIPOPEPTIDE VACCINE W/ ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS$35,553
M01 · FY2000 · RR
BONE MARROW DONORS &VOLUNTEERS FOR STUDY OF CMV$35,553
M01 · FY2000 · RR
LIPOPEPTIDE VACCINE W/ ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS$0
M01 · FY2000 · RR
BONE MARROW DONORS &VOLUNTEERS FOR STUDY OF CMV$0
M01 · FY2000 · RR
ACQUISITION OF IMMUNITY TO CYTOMEGALOVIRUS$0
P01 · FY2000 · CA